João Cândido Spezia de Souza

João Cândido Spezia de Souza

Auto-generated profile, based on publicly available information

João Cândido Spezia de Souza

Faculty of Medicine, Federal University of Santa Catarina

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in Neuroradiology
Verified
Journal Article
Closed access
PDF file
NLNatan Lucca Lima
Natan Lucca Lima
MMMarcos Henrique da Silva Mezzari
Marcos Henrique da Silva Mezzari
LJLuís Cláudio Izidio Costa Júnior
Luís Cláudio Izidio Costa Júnior
DGDavi Orli Machado Grüdtner
Davi Orli Machado Grüdtner
BMBárbara Ghizoni Maggi
Bárbara Ghizoni Maggi
GIGustavo R. Isolan
Gustavo R. Isolan

20 November 2025 in Journal of Chemotherapy
Verified
Journal Article
Closed access
MMMarcos Henrique da Silva Mezzari
Marcos Henrique da Silva Mezzari
NLNatan Lucca Lima
Natan Lucca Lima
BMBárbara Ghizoni Maggi
Bárbara Ghizoni Maggi
DGDavi Orli Machado Grüdtner
Davi Orli Machado Grüdtner
JSJoão Cândido Spezia de Souza
João Cândido Spezia de Souza
GIGustavo R. Isolan
Gustavo R. Isolan
Glioblastoma is an aggressive brain tumor with median survival under 2 years despite standard therapy. At recurrence, treatment options are limited, and regorafenib has emerged as a promising option. A systematic search was conducted through Pubmed, Cochrane Library, Embase, and Web of Science for studies on regorafenib in adult recurrent glioblastoma, and a single-arm meta-analysis with random-effects model was performed to pool the data. Across ten studies (724 patients), median overall survival (OS) was 7.2 months and median progression-free survival (PFS) was 2.6 months, with a 12-month OS of 22.5% and a 6-month PFS of 14.9%. Disease control rate (DCR) was 36.1%, including stable disease (SD) of 26.6% and a partial response of 8.5%; progressive disease occurred in 60.9%, and grade 3-4 adverse events in 31.4%. Meta-regression suggested MGMT methylation was associated with improved OS, PFS, DCR, and SD, while male sex was associated with better OS and SD. Overall, regorafenib demonstrated a predictable safety profile in recurrent glioblastoma, with outcomes potentially improved in male patients with MGMT-methylated tumors.

7 September 2026 in Epilepsy & Behavior
Verified
Journal Article
Closed access
JSJoão Cândido Spezia de Souza
João Cândido Spezia de Souza
MZMarina Ilha Zimmermann
Marina Ilha Zimmermann
NLNatan Lucca Lima
Natan Lucca Lima
MGMaruí Weber Corseuil Giehl
Maruí Weber Corseuil Giehl
ACAna Carolina Lobor Cancelier
Ana Carolina Lobor Cancelier